Journal
CURRENT OPINION IN MICROBIOLOGY
Volume 33, Issue -, Pages 41-46Publisher
CURRENT BIOLOGY LTD
DOI: 10.1016/j.mib.2016.06.001
Keywords
-
Categories
Funding
- Shriners Hospital Postdoctoral Fellowship [84206]
- Cystic Fibrosis Foundation fellowship [BALLOK15F0]
- Shriners [8770]
- Cystic Fibrosis Foundation [11P0]
- NIAID [R33AI105902, R56AI063433]
Ask authors/readers for more resources
As antibiotic resistance remains a major public health threat, anti-virulence therapy research is gaining interest. Hundreds of potential anti-virulence compounds have been examined, but very few have made it to clinical trials and none have been approved. This review surveys the current anti-virulence research field with a focus on the highly resistant and deadly ESKAPE pathogens, especially Pseudomonas aeruginosa. We discuss timely considerations and caveats in anti-virulence drug development, including target identification, administration, preclinical development, and metrics for success in clinical trials. Development of a defined pipeline for anti-virulence agents, which differs in important ways from conventional antibiotics, is imperative for the future success of these critically needed drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available